Regeneron Pharmaceuticals and Sanofi-Aventis have entered a new collaboration, which will include a greater SA stake in the biopharma. The companies will work to discover, develop, and commercialize fully-human therapeutic antibodies utilizing Regeneron’s proprietary VelociSuite of technologies. SA will also make an $85 million upfront payment to Regeneron and will fund as much as $475 million of research during the next five years. SA will have an option to extend the research agreemen...